AstraZeneca COVID-19 antibody drug offers 83% protection over six month period
New data from AstraZeneca’s COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials have revealed high efficacy from a dose of the long acting antibody (LAAB) combination.
In an analysis of the ongoing PROVENT trial, it was found that one 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.
About 2% of the global population is considered to have a heightened risk of an inadequate response to a COVID-19 vaccine. This includes people with blood cancers or other cancers being treated with chemotherapy, patients on dialysis, those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.
Lees het gehele artikel op: AstraZeneca COVID-19 antibody drug offers 83% protection over six month period | Pharmafile